Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in Pulmonary Emphysema
NCT03244059Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Aug 2018
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary emphysema comparing Belimumab with Placebo (2 arms). Primary endpoint: Percent Change of Circulating Anti-GRP78 IgG Levels at Day 210. Started Aug 2018; status: completed.
02
Drugs
belimumab
03
Conditions
pulmonary emphysema
Beyond the preview
Go deeper on NCT03244059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244059.